Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Feb 25

PMID 35203457

Authors

Armando Tripodi

Rosa Lombardi

Massimo Primignani

Vincenzo La Mura

Flora Peyvandi

Anna L Fracanzani

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and it is anticipated that it could become even more prevalent in parallel with an increase in the incidence of metabolic diseases closely related to NAFLD, such as obesity, type II diabetes, dyslipidemia, and arterial hypertension. In addition to liver impairment, NAFLD is associated with cardiovascular diseases. Fibrosis, atherosclerosis, and venous thrombosis are basically the pathogenic mechanisms behind these clinical manifestations, and all are plausibly associated with hypercoagulability that may, in turn, develop because of an imbalance of pro- vs. anticoagulants and the presence of such procoagulant molecular species as microvesicles, neutrophil extracellular traps (NETs), and inflammation. The assessment of hypercoagulability by means of thrombin generation is a global procedure that mimics the coagulation process occurring in vivo much better than any other coagulation test, and is considered to be the best candidate laboratory tool for assessing, with a single procedure, the balance of coagulation in NAFLD. In addition to defining the state of hypercoagulability, the assessment of thrombin generation could also be used to investigate, in clinical trials, the best approach (therapeutic and/or lifestyle changes) for minimizing hypercoagulability and, hence, the risk of cardiovascular diseases, progression to atherosclerosis, and liver fibrosis in patients with NAFLD.

Citing Articles

Neutrophil extracellular traps in homeostasis and disease.

Wang H, Kim S, Lei Y, Wang S, Wang H, Huang H Signal Transduct Target Ther. 2024; 9(1):235.

PMID: 39300084 PMC: 11415080. DOI: 10.1038/s41392-024-01933-x.

Impact of Cirrhosis Etiology on the Risk for Venous Thromboembolism.

Pemmasani G, Tremaine W, Karagozian R, John S Dig Dis Sci. 2024; 69(7):2691-2698.

PMID: 38700633 DOI: 10.1007/s10620-024-08440-7.

Endotoxemia and Platelets: 2 Players of Intrahepatic Microthrombosis in NAFLD.

Violi F, Pastori D, Pignatelli P, Cammisotto V JACC Basic Transl Sci. 2024; 9(3):404-413.

PMID: 38559621 PMC: 10978333. DOI: 10.1016/j.jacbts.2023.07.003.

Regulation of Benzo[a]pyrene-Induced Hepatic Lipid Accumulation through CYP1B1-Induced mTOR-Mediated Lipophagy.

Bu K, Kim M, Shin M, Lee S, Sung J Int J Mol Sci. 2024; 25(2).

PMID: 38279324 PMC: 10816991. DOI: 10.3390/ijms25021324.

Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines.

Pezzino S, Luca T, Castorina M, Puleo S, Latteri S, Castorina S Life (Basel). 2024; 14(1).

PMID: 38255708 PMC: 10820028. DOI: 10.3390/life14010093.

References

Umbro I, Fabiani V, Fabiani M, Angelico F, Ben M . Association between non-alcoholic fatty liver disease and obstructive sleep apnea. World J Gastroenterol. 2020; 26(20):2669-2681. PMC: 7265151. DOI: 10.3748/wjg.v26.i20.2669. View

Hemker H, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R . Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003; 33(1):4-15. DOI: 10.1159/000071636. View

Le M, Yeo Y, Li X, Li J, Zou B, Wu Y . 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021; 20(12):2809-2817.e28. DOI: 10.1016/j.cgh.2021.12.002. View

Kopec A, Abrahams S, Thornton S, Palumbo J, Mullins E, Divanovic S . Thrombin promotes diet-induced obesity through fibrin-driven inflammation. J Clin Invest. 2017; 127(8):3152-3166. PMC: 5531415. DOI: 10.1172/JCI92744. View

Tripodi A, Primignani M, Chantarangkul V, DellEra A, Clerici M, De Franchis R . An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology. 2009; 137(6):2105-11. DOI: 10.1053/j.gastro.2009.08.045. View

Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F . Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2015; 31(5):936-44. DOI: 10.1111/jgh.13264. View

Tripodi A, Pellegatta F, Chantarangkul V, Grigore L, Garlaschelli K, Baragetti A . Statins decrease thrombin generation in patients with hypercholesterolemia. Eur J Intern Med. 2014; 25(5):449-51. DOI: 10.1016/j.ejim.2014.03.016. View

Levi M, van der Poll T . Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med. 2005; 15(7):254-9. DOI: 10.1016/j.tcm.2005.07.004. View

Schmidt M, Cannegieter S, Johannesdottir S, Dekkers O, Horvath-Puho E, Sorensen H . Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study. J Thromb Haemost. 2014; 12(8):1207-15. DOI: 10.1111/jth.12604. View

10.

Byrne C, Targher G . NAFLD as a driver of chronic kidney disease. J Hepatol. 2020; 72(4):785-801. DOI: 10.1016/j.jhep.2020.01.013. View

11.

Luci C, Bourinet M, Leclere P, Anty R, Gual P . Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies. Front Endocrinol (Lausanne). 2021; 11:597648. PMC: 7771356. DOI: 10.3389/fendo.2020.597648. View

12.

Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H . Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2013; (12):CD008623. DOI: 10.1002/14651858.CD008623.pub2. View

13.

Allen A, Hicks S, Mara K, Larson J, Therneau T . The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study. J Hepatol. 2019; 71(6):1229-1236. PMC: 6921701. DOI: 10.1016/j.jhep.2019.08.018. View

14.

Miele L, Vallone S, Cefalo C, La Torre G, Di Stasi C, Vecchio F . Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009; 51(4):778-86. DOI: 10.1016/j.jhep.2009.06.008. View

15.

Pais R, Giral P, Khan J, Rosenbaum D, Housset C, Poynard T . Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol. 2016; 65(1):95-102. DOI: 10.1016/j.jhep.2016.02.023. View

16.

Eguchi A, Feldstein A . Extracellular vesicles in non-alcoholic and alcoholic fatty liver diseases. Liver Res. 2018; 2(1):30-34. PMC: 6190912. DOI: 10.1016/j.livres.2018.01.001. View

17.

van Montfoort M, Stephan F, Lauw M, Hutten B, van Mierlo G, Solati S . Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis. Arterioscler Thromb Vasc Biol. 2012; 33(1):147-51. DOI: 10.1161/ATVBAHA.112.300498. View

18.

Targher G, Byrne C, Lonardo A, Zoppini G, Barbui C . Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016; 65(3):589-600. DOI: 10.1016/j.jhep.2016.05.013. View

19.

Kopec A, Joshi N, Towery K, Kassel K, Sullivan B, Flick M . Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice. J Pharmacol Exp Ther. 2014; 351(2):288-97. PMC: 4201275. DOI: 10.1124/jpet.114.218545. View

20.

Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than T . Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019; 70(4):1457-1469. PMC: 6766425. DOI: 10.1002/hep.30626. View